~~<i id='618706C883'><strike id='618706C883'><tt id='618706C883'><pre id='618706C883'></pre></tt></strike></i>~~

Home» comprehensive» fashion

fashion

author：Wikipedia 2025-09-30 09:48:10 Page View：5345

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The FDA weighs the risks of candy
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

explore

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

First Opinion Podcast: How to protect health care in times of war

Injusttwoweeks,thebrutalityoftheIsrael-Hamasconflicthasshockedtheworld.Butoneofitsmostheartbreakinga

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

Use doctors trained outside the U.S. to ease the physician shortage

AdobeThislegislativesession,Gov.BillLeemadehistorybysigningabillthatmakesTennesseethefirststateinthe